EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Innovation Pharmaceuticals's Enterprise Value is $1.55 Mil.
Innovation Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.05 Mil. Therefore, Innovation Pharmaceuticals's EV-to-FCF for today is -0.76.
The historical rank and industry rank for Innovation Pharmaceuticals's EV-to-FCF or its related term are showing as below:
IPIX'
s EV-to-FCF Range Over the Past 10 Years
Min: -31.14 Med: -2.48 Max: 0.55
Current: -0.76
During the past 13 years, the highest EV-to-FCF of Innovation Pharmaceuticals was 0.55. The lowest was -31.14. And the median was -2.48.
IPIX's EV-to-FCF is ranked worse than 100% of 389
companies
in the Biotechnology industry
Industry Median: 4.27
vs IPIX: -0.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Innovation Pharmaceuticals's stock price is $0.0035.
Innovation Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.009. Therefore, Innovation Pharmaceuticals's PE Ratio for today is At Loss.
Innovation Pharmaceuticals EV-to-FCF Historical Data
The historical data trend for Innovation Pharmaceuticals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innovation Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovation Pharmaceuticals EV-to-FCF Distribution
For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Innovation Pharmaceuticals's EV-to-FCF falls into.
Innovation Pharmaceuticals EV-to-FCF Calculation
Innovation Pharmaceuticals's EV-to-FCF for today is calculated as:
Innovation Pharmaceuticals's current Enterprise Value is $1.55 Mil.
Innovation Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Innovation Pharmaceuticals's PE Ratio for today is calculated as:
Innovation Pharmaceuticals's share price for today is $0.0035.
Innovation Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Innovation Pharmaceuticals EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Innovation Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IPIX has been successfully added to your 